(Boursier.com) — Sanofi announces that it has filed its 2022 Universal Registration Document containing the Annual Financial Report with the Autorité des marchés financiers (AMF) in France and its “Form 20-F” with the “Securities and Exchange Commission” in the United States.
On February 22, 2023, the Food and Drug Administration (FDA) approved ALTUVIIIO. This event confirms the significant increase in the value of the asset. This decision, which took place before the filing of the universal registration document and the “Form 20-F”, gave rise to an adjustment to the IFRS net income for the 2022 financial year, presented in the press release of February 3, 2023, corresponding the reversal of the impairment of intangible assets related to the Eloctate franchise for an amount of 2,154 million euros, in accordance with IAS36 Impairment of Assets.
These assets had been partially impaired in 2019. The adjustment is presented on the Impairment of intangible assets line of the income statement. The net impact after tax represents a gain of 1,651 million euros.
This change has no impact on cash flows. Following this adjustment, for the year 2022, the IFRS net income amounts to 8,371 million euros (compared to 6,720 million euros in the press release of February 3, 2023), the net earnings per share (IFRS EPS ) at 6.69 euros (compared to 5.37 euros in the press release of February 3, 2023), total equity at 75,152 million euros (compared to 73,512 million euros in the press release of February 3, 2023).
Net income from activities (non-IFRS indicator) for the 2022 financial year is unchanged, as is the amount of the dividend proposed by the Board of Directors on February 2, 2023.
©2023 Boursier.com